The role of gefitinib in the management of Asian patients with non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 17, Issue 3, 2008, Pages 401-411

  Chang, Alex Y ^a,b  

^a Johns Hopkins Singapore   (Singapore)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Asian patients; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; ITRACONAZOLE; METOPROLOL; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; RANITIDINE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ACNE; ADJUVANT THERAPY; ANOREXIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NAUSEA; NUMERICAL CHROMOSOME ABERRATION; OVERALL SURVIVAL; PROTEIN DEPHOSPHORYLATION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; ASIAN; DRUG ANTAGONISM; ETHNOLOGY; GENETICS; LUNG TUMOR; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 40949147677     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.3.401     Document Type: Review

References (98)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In: Ede DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. 7th edition. Philadelphia, USA: Lippincott Williams and Welkins; 2005. p. 753-810
3. Catherine D, Stefan M, Estelle R, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;17:CD004569
4. Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227s-4232s
5. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65
6. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-7
7. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46
8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
10. Marx J. Medicine. Why a new cancer drug works well, in some patients. Science 2004;304:658-9
11. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20
12. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
13. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203
14. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
15. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
16. Sonobe M, Manabe T, Wada H, et al. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005;93:355-63
17. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45
18. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
19. Crowley J, Furusek, Kawahara M, et al. Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC): a model for testing population-based pharmaco-genomics [Abstract 7050]. Proc ASCO 2006;24(18S):376S
20. Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14:449-54
21. Scagliotti G, Purvish P, von Pawel J, et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 4:S306
22. Gronberg BH, Bremnes R, Aasebo U, et al.; A Phase III Study by the Norwegian Lung Cancer Group. Pemetrexed + carboplatin vs gemcitabine + carboplatin as first line chemotherapy in stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 4:S317
23. Cho BC, Im C-K, Park M-S, et al. Phase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitnib. J Clin Oncol 2007;25:2528-33
24. Choong NW, Dietrich S, Seiwert T, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-7
25. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32
26. Gridelli C, Rossi A, Maione P, et al. Erlotinib in non-small cell lung cancer. Expert Opin Pharmacother 2007;8:2579-92
27. Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8
28. Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week-on, 2-week-off schedule in patients with advanced solid tumors. Br J Cancer 2007;98:80-5
29. Kobayashi S, Shimamura T, Monti S, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signalling. Cancer Res 2006;66:11389-98
30. Moasser MM, Basso AI, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2 driven signalling and suppresses the growth of HER-2 overexpressing tumor cells. Cancer Res 2001;61:7184-8
31. Normanno N, Campiglio M, De Luca A, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72
32. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8
33. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2001;20:110-24
34. Daneshmand M, Parolin DAE, Hitte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003;9:2457-64
35. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid; malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50
36. Herbst RS, Maddox A-M, Rothenbere ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25
37. Baselga J, Rischin D, Ranson M, et al. Phase I safety pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302
38. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa" ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-30
39. Shinagawa N, Yamazaki Y, Asahina H, et al. Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 2007;58:422-4
40. Rossi A, Maione P, Del Gaizo F, et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005;47:421-3
41. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small cell lung cancer. Curr Med Res Opin 2006;22:561-73
42. Armour A. Gefitinib in advanced non-small cell lung cancer: clinical experience in patients of Asian origin. Asia Pacific J Clin Oncol 2007;3:66-78
43. Yang C-H, Shih J-Y, Chen K-C, et al. Survival outcome and predictors of gefitinib antitumor activity in east Asian chemonaive patients with advanced non-small cell lung cancer. Cancer 2006;107:1873-82
44. Kimura H, Kasahara B, Shibata K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy naïve non-small cell lung cancer. J Thorac Oncol 2006;1:260-7
45. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small cell lung cancer: a Phase II study. J Clin Oncol 2006;24:64-9
46. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never smokers. Clin Cancer Res 2005;11:3032-7
47. Reck M, Buchbolz E, Schott-von-Romer K, et al. Gefitinib monotherapy in chemotherapy-naïve patients with inoperable stage III/IV non-small cell lung cancer. Clin Lung Cancer 2006;6:406-11
48. Katakami N, Okazaki M, Kinose D, et al. A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-based regimen [Abstract]. Proc Am Soc Clin Oncol 2003;22:2679
49. Goto K, Kim E, Kubota K, et al. Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer [Abstract 7098]. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22(14S)
50. Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small cell lung cancer. Lung Cancer 2004;46:255-61
51. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43
52. Kaneda H, Tamura K, Kurata T, et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2004;46:247-54
53. Kim YH, Ishii G, Goto K, et al. Dominant papilliary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004;10:7311-7
54. Matsuura K, Kudoh S, Mitsuoka S, et al. Evaluating a prognostic factor in advanced adenocarcinoma of the lung treated with gefitinib [Abstract 7334]. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22(14S)
55. Kishi K, Homma S, Miyamoto A, et al. Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC) [Abstract 7095]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S)
56. Nakagawa M, Teramukai S, Tada H, et al. Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during [gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study [Abstract 7190]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S)
57. Hotta K, Matsuo K, Ueoka H, et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005;16:1817-23
58. Fujiwara Y, Kiura K, Toyooka S, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced small cell lung cancer. Lung Cancer 2006;52:99-103
59. Mu X-L, Li L-Y, Zhang X-T, et al. Evaluation of safety and efficacy of gefitinib ('IRESSA', ZD1839) as monotherapy in a series of Chinese patients with advanced non-small cell lung cancer: experience from a compassionate-use programme. BMC Cancer 2004;4:51-9
60. Wu YL, Yang Y, Yang J-J, et al. ZD1839 for the treatment of heavily pretreated non-small cell lung cancer [Abstract 7341]. ASCO Annual Proceedings. J Clin Oncol 2004;22(14S)
61. Wang MZ, Li LY, Wang SL, et al. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2006;119:63-8
62. Zhang XT, Li LY, Chang X-Y, et al. Efficacy and correlation with predictive markers of gefitinib in pretreated Chinese patients with advanced NSCLC [Abstract 7240]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S)
63. Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-8
64. Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005;11:2244-51
65. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non small cell lung cancer. Int J Cancer 2005;113:109-15
66. Chang G-C, Chen K-C, Yang T-Y, et al. Activity of gefitinib in advanced non-small cell lung cancer with very poor performance status. Invest New Drugs 2005;23:73-7
67. Chiu C-H, Tsai C-M, Chen Y-M, et al. Gefitinib is active in patients with brain metascases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005;47:129-38
68. Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib anti-tumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol 2006;1:520-5
69. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24
70. Sunaga N, Tomizawa Y, Yonagitani N, et al. Phase II prospective study of efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-9
71. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6
72. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as the first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004
73. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007;2:22-8
74. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
75. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (Iressa) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55
76. Douillard J-Y, Kim E, Hirsh V, et al. Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). J Thorac Oncol 2007;2 Suppl 4:S305
77. SeKine I, Ichinose Y, Nishiwaki Y, et al. A randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 4:S339
78. Forsythe B, Faul Kner K. Overview of the tolerability of gefitinib (Iressa™) monotherapy. Clinical experience in non-small cell lung cancer. Drug Saf 2004;27:1081-92
79. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, anti-tumor response and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56
80. Zhang X, Chang A. Somatic mutations of the epidermal growth factor receptor and non-small cell lung cancer. J Med Genet 2007;44:166-72
81. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44
82. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinoma with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501
83. Bean J, Brennan C, Shih J-Y, et al. MET amplification occurs with or without T790M mutation in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
84. Sone T, Kasahara K, Kimura, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with non-small cell lung cancer. Cancer 2007;109:1836-44
85. Takano T, Ohe Y, Tsuta K, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 2007;13:5385-90
86. Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumor derived DNA from pleural effusion is a practical basis for predicting response to gefitinib. Br J Cancer 2006;95:1390-5
87. Chin TM, Armar D, Soo R, et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 2007;53:62-70
88. Zhang X, Zhao Y, Wang M, et al. Detection and comparison of epidermal growth factor receptor mutations between cells and fluid of malignant pleural effusion from non-small cell lung cancer. Lung Cancer 2007; Nov 29 [Epub ahead of print]
89. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. Clin Cancer Res 2007;13:4954-5
90. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84
91. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:786-94
92. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
93. Gatzemeier U, Pluzanska, Szcaesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the rarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-52
94. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92
95. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
96. Kelly K, Chansky K, Gaspar LE, et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definite chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer [Abstract 7513]. J Clin Oncol 2007;15:388S
97. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small-cell lung cancer. Clin Cancer Res 2007;13:2684-91
98. Kris MG, Riely GJ, Azzoli CG, et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial [Abstract 7575]. J Clin Oncol 2007;25:403s